Central retinal artery occlusion can result in permanent vision loss. Effective treatment is lacking. We conducted a phase 3, double-blind, double-dummy, randomized, controlled trial involving ...

AIM: The “2026 Guideline for the Early Management of Patients With AIS” replaces the “2018 Guidelines for the Early Management of Patients With AIS” and the 2019 update to reflect recent advances in ...

What Is Fesilty, and Why Does It Matter? Fesilty (fibrinogen, human-chmt) is a newly approved treatment for sudden bleeding episodes in both children and adults with a rare condition called congenital ...

Sanofi SAN-1.04%decrease; red down pointing triangle said two bleeding disorder treatments for both chronic and acute conditions have been approved in China, expanding its hematology offerings in the ...

Two bleeding disorder treatments for both chronic and acute conditions, Qfitlia and Cablivi, have been approved in China. Broadcom Reports Earnings After the Close Today. Analysts Expect Strong ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Star Therapeutics, a late clinical-stage biotechnology company discovering and developing best-in-class antibodies for bleeding disorders and other ...

Despite the considerable disease burden associated with hereditary hemorrhagic telangiectasia, no therapies are licensed for treatment. In a proof-of-concept, placebo-controlled trial, the ...

Hereditary hemorrhagic telangiectasia (HHT) is the second most common inherited bleeding disorder worldwide, affecting 1 in 3,800 persons. HHT’s hallmark symptom is chronic nosebleeds, which often ...

Hereditary hemorrhagic telangiectasia (HHT) is the second most common inherited bleeding disorder worldwide, affecting 1 in 3,800 persons. HHT's hallmark symptom is chronic nosebleeds, which often ...

Bleeding occurs when trauma damages a blood vessel. When that trauma involves your head—whether the scalp, skull, or brain—it’s considered a head injury. These head injuries range in severity from a ...